ePrints

Erratum: Correction: Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer (Oncotarget (2017) 8 41 (69779-69796))

Lookup NU author(s): Maryam Zanjirband Zanjirband, Professor Nicola CurtinORCiD, Professor John LunecORCiD

Downloads

• Published version [.pdf]

Licence

This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).

Publication metadata

Author(s): Zanjirband M, Curtin N, Edmondson RJ, Lunec J

Publication type: Note

Publication status: Published

Journal: Oncotarget

Year: 2024

Volume: 15

Pages: 142-142

Online publication date: 22/02/2024

Acceptance date: 02/04/2018

ISSN (electronic): 1949-2553

URL: https://doi.org/10.18632/oncotarget.28523

DOI: 10.18632/oncotarget.28523

PubMed id: 38386812

Share